{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:32:13Z","timestamp":1793741533323,"version":"4.6.1"},"reference-count":49,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Fosfomycin is used as a combination partner for the treatment of severe non-urinary tract infections. Individualized dosing of fosfomycin based on therapeutic drug monitoring (TDM) has the potential to reduce drug-related adverse events (AEs). Methods: This retrospective study used routine data from patients receiving intravenous fosfomycin therapy. Plasma concentrations of fosfomycin were categorized into three different ranges: &lt;64 mg\/L, 64\u2013128 mg\/L, and &gt;128 mg\/L. Subsequently, the influence of acute kidney injury (AKI) on reaching the specific plasma concentration ranges and the occurrence of AEs was analyzed. Results: The study included 143 patients (median age 73 years, 66.4% male) with fosfomycin plasma measurements. Beta-lactam antibiotics were most frequently used in combination (62.2%), followed by tetracyclines (12.2%), cotrimoxazole (8.1%), and other agents (17.5%). Fosfomycin concentrations were &gt;128 mg\/L in 45% (36\/80) of patients with normal renal function, 70.4% (38\/54) of patients with AKI stages I to III, and 77.8% (7\/9) of patients with renal replacement therapy. AEs occurred in 54% (77\/143), mainly hypernatremia (42.6%), hypokalemia (39.9%), and gastrointestinal symptoms (19.6%), with the median fosfomycin plasma concentration being significantly higher in patients with AEs (158 mg\/L vs. 131 mg\/L, p = 0.01). Multivariate logistic regression analysis revealed that patients aged \u226570 years (OR 3.70, 95% CI 1.24\u201311.5; p = 0.02) and patients with fosfomycin plasma concentrations &gt; 128 mg\/L (OR 3.30, 95% CI 1.09\u201310.4; p = 0.04) had a higher risk of AEs. Conclusions: There was a significant association between high plasma exposure and the occurrence of AEs. In particular, the impact of acute renal insufficiency on fosfomycin plasma concentrations should be considered. Individualized fosfomycin dosing based on TDM and the intensive monitoring of renal function contribute to reducing drug-related side effects.<\/jats:p>","DOI":"10.3390\/antibiotics14060548","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T03:52:08Z","timestamp":1748404328000},"page":"548","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Monitoring Plasma Concentrations of Intravenously Administered Fosfomycin to Prevent Drug-Related Adverse Events: A Retrospective Observational Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Kathrin","family":"Marx","sequence":"first","affiliation":[{"name":"Hospital Pharmacy, Hospital St. Georg, 04129 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Malmstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Tropical Medicine, Hospital St. Georg, 04129 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Quast","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, Hospital St. Georg, 04129 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Glas","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hospital St. Georg, 04129 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1600-6581","authenticated-orcid":false,"given":"Ralph","family":"Wendt","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital St. Georg, 04129 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kinzig","sequence":"additional","affiliation":[{"name":"Institute for Biomedical and Pharmaceutical Research, 90562 Nuremberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"S\u00f6rgel","sequence":"additional","affiliation":[{"name":"Institute for Biomedical and Pharmaceutical Research, 90562 Nuremberg, Germany"},{"name":"Institute of Pharmacology, West German Heart and Vascular Center, University of Duisburg-Essen, 45141 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Fedders","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, Hospital St. Georg, 04129 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4930-6655","authenticated-orcid":false,"given":"Thilo","family":"Bertsche","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Institute of Pharmacy, Leipzig University, 04109 Leipzig, Germany"},{"name":"Drug Safety Center, Leipzig University Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6942-5785","authenticated-orcid":false,"given":"Christoph","family":"L\u00fcbbert","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Tropical Medicine, Hospital St. Georg, 04129 Leipzig, Germany"},{"name":"Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Leipzig University Medical Center, 04103 Leipzig, Germany"},{"name":"Interdisciplinary Center for Infectious Diseases, Leipzig University Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijantimicag.2018.09.013","article-title":"Resistance to fosfomycin: Mechanisms, Frequency and Clinical Consequences","volume":"53","author":"Falagas","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2147\/TCRM.S199119","article-title":"Fosfomycin: The characteristics, activity, and use in critical care","volume":"15","author":"Hashemian","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ijantimicag.2009.08.013","article-title":"Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections","volume":"34","author":"Roussos","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Dijkmans, A.C., Zacar\u00edas, N.V.O., Burggraaf, J., Mouton, J.W., Wilms, E.B., van Nieuwkoop, C., Touw, D.J., Stevens, J., and Kamerling, I.M.C. (2017). Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics, 6.","DOI":"10.3390\/antibiotics6040024"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_6","first-page":"296","article-title":"Stellenwert von Fosfomycin f\u00fcr die Therapie von Erkrankungen durch multiresistente gramnegative Bakterien","volume":"30","author":"Stock","year":"2012","journal-title":"Arzneimitteltherapie"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Zhanel, G.G., Walkty, A.J., and Karlowsky, J.A. (2016). Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis. Can. J. Infect. Dis. Med. Microbiol., 2016.","DOI":"10.1155\/2016\/2082693"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1128\/AAC.47.9.2850-2858.2003","article-title":"Biological costs and mechanisms of fosfomycin resistance in Escherichia coli","volume":"47","author":"Nilsson","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","unstructured":"Koch-Institut, R. (2025, April 11). ARS\u2014Antibiotika-Resistenz-Surveillance, Resistenzstatistik 2008\u20132022. Available online: https:\/\/ars.rki.de\/Content\/Database\/ResistanceOverview.aspx."},{"key":"ref_10","unstructured":"Fachinformation INFECTOFOS 2g\/3g\/5g\/8g (2025, April 11). Firma Infectopharm Arzneimittel und Consilium GmbH. Informationsstand: 07\/2021. Available online: https:\/\/www.fachinfo.de\/pdf\/009537."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00228-010-0794-5","article-title":"Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria","volume":"66","author":"Kastoris","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijantimicag.2010.09.002","article-title":"Adverse events associated with intravenous fosfomycin","volume":"37","author":"Florent","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40121-015-0092-8","article-title":"Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database","volume":"4","author":"Iarikov","year":"2015","journal-title":"Infect. Dis. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijantimicag.2013.05.018","article-title":"What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review","volume":"42","author":"Parker","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s10096-021-04181-x","article-title":"Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: A systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies","volume":"40","author":"Antonello","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/1120009X.2021.1963617","article-title":"Fosfomycin therapeutic drug monitoring in real-life: Development and validation of a LC-MS\/MS method on plasma samples","volume":"34","author":"Baldelli","year":"2022","journal-title":"J. Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Rinaldi, M., Cojutti, P.G., Zamparini, E., Tedeschi, S., Rossi, N., Conti, M., Giannella, M., Pea, F., and Viale, P. (2023). Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction. Antimicrob. Agents Chemother., 65.","DOI":"10.1128\/AAC.02038-20"},{"key":"ref_18","first-page":"8","article-title":"New microbiological aspects of fosfomycin","volume":"32","year":"2019","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lepak, A.J., Zhao, M., VanScoy, B., Taylor, D.S., Ellis-Grosse, E., Ambrose, P.G., and Andes, D.R. (2017). In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.00476-17"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijantimicag.2006.05.019","article-title":"Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections","volume":"28","author":"Mazzei","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1128\/AAC.00355-16","article-title":"Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model","volume":"60","author":"VanScoy","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Gatti, M., Giannella, M., Rinaldi, M., Gaibani, P., Viale, P., and Pea, F. (2022). Pharmacokinetic\/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream I. Antibiotics, 11.","DOI":"10.3390\/antibiotics11121739"},{"key":"ref_23","unstructured":"European Committee for Antimicrobial Susceptibility Testing (2025, April 11). Fosfomycin Intravenous. Rationale for EUCAST Clinical Breakpoints. Version 1.0; November 2023. Available online: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Rationale_documents\/Fosfomycin_iv_Rationale_Document_v1.0_20231123.pdf."},{"key":"ref_24","unstructured":"European Committee for Antimicrobial Susceptibility Testing (2025, April 11). EUCAST Guidance on Use of Fosfomycin i.v. Breakpoints. Available online: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Guidance_documents\/Use_of_fosfomycin_iv_breakpoints_General_advice_20231127.pdf."},{"key":"ref_25","unstructured":"European Committee for Antimicrobial Susceptibility Testing (2025, April 11). MIC EUCAST: Antimicrobial Wild Type Distributions of Microorganisms. Available online: https:\/\/mic.eucast.org\/search\/."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Al Jalali, V., Matzneller, P., Wulkersdorfer, B., Chou, S., Bahmany, S., Koch, B.C.P., and Zeitlinger, M. (2020). Clinical Pharmacokinetics of Fosfomycin after Continuous Infusion Compared with Intermittent Infusion: A Randomized Crossover Study in Healthy Volunteers. Antimicrob. Agents Chemother., 65.","DOI":"10.1128\/AAC.01375-20"},{"key":"ref_27","first-page":"19","article-title":"Deciphering pharmacokinetics and pharmacodynamics of fosfomycin","volume":"32","year":"2019","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00228-023-03477-5","article-title":"Population plasma and urine pharmacokinetics and the probability of target attainment of fosfomycin in healthy male volunteers","volume":"79","author":"Edwina","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Cojutti, P.G., Tedeschi, S., Zamparini, E., Fornaro, G., Zagarrigo, M., De Paolis, M., Viale, P., and Pea, F. (2025). Could a Reduced Dose of 8 g of Continuous Infusion Fosfomycin Be Considered as Effective as and Safer than a Standard 16 g Dose When Combined with High-Dose Daptomycin in the Treatment of Staphylococcal osteoarticular Infections?. Antibiotics, 14.","DOI":"10.3390\/antibiotics14020139"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"K\u00f6nig, C., Martens-Lobenhoffer, J., Czorlich, P., Westphal, M., Bode-B\u00f6ger, S.M., Kluge, S., and Grensemann, J. (2023). Cerebrospinal fluid penetration of fosfomycin in patients with ventriculitis: An observational study. Ann. Clin. Microbiol. Antimicrob., 22.","DOI":"10.1186\/s12941-023-00572-4"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1128\/AAC.01321-15","article-title":"Population Pharmacokinetics of Fosfomycin in Critically Ill Patients","volume":"59","author":"Parker","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13613-023-01129-6","article-title":"Pathogen-based target attainment of optimized continuous infusion dosing regimens of piperacillin-tazobactam and meropenem in surgical ICU patients: A prospective single center observational study","volume":"13","author":"Verhaeghe","year":"2023","journal-title":"Ann. Intensive Care."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s15010-019-01352-z","article-title":"Therapeutic drug monitoring-guided continuous infusion of piperacillin\/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: A retrospective analysis of four years of clinical experience","volume":"47","author":"Richter","year":"2019","journal-title":"Infection"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Weinelt, F.A., Stegemann, M.S., Theloe, A., Pf\u00e4fflin, F., Achterberg, S., Weber, F., D\u00fcbel, L., Mikolajewska, A., Uhrig, A., and Kiessling, P. (2022). Evaluation of a meropenem and piperacillin monitoring program in intensive care unit patients calls for the regular assessment of empirical targets and easy-to-use dosing decision tools. Antibiotics, 11.","DOI":"10.3390\/antibiotics11060758"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1378\/chest.11-1671","article-title":"Subtherapeutic initial beta-lactam concentrations in select critically ill patients: Association between augmented renal clearance and low trough drug concentrations","volume":"142","author":"Udy","year":"2012","journal-title":"Chest"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coph.2015.06.002","article-title":"Augmented renal clearance in critically ill patients: Etiology, definition and implications for beta-lactam dose optimization","volume":"24","author":"Sime","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"106569","DOI":"10.1016\/j.ijantimicag.2022.106569","article-title":"Recommended antibiotic dosage regimens in critically ill patients with augmented renal clearance: A systematic review","volume":"59","author":"Silva","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Chen, T.T., Chang, Y.F., and Wu, Y.C. (2023). Clinical Use of Intravenous Fosfomycin in Critical Care Patients in Taiwan. Pathogens, 12.","DOI":"10.3390\/pathogens12060841"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Biscarini, S., Mangioni, D., Bobbio, C., Mela, L., Alagna, L., Baldelli, S., Blasi, F., Canetta, C., Ceriotti, F., and Gori, A. (2024). Adverse events during intravenous fosfomycin therapy in a real-life scenario. Risk factors and the potential role of therapeutic drug monitoring. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09541-4"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e20230727","DOI":"10.1590\/1806-9282.20230727","article-title":"Evaluation of the combination treatments with intravenous fosfomycin for carbapenem-resistant Klebsiella pneumoniae","volume":"69","author":"Kaya","year":"2023","journal-title":"Rev. Assoc. Med. Bras."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/cid\/ciz181","article-title":"Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2\/3 Randomized Trial","volume":"69","author":"Kaye","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/1120009X.2022.2149186","article-title":"Efficacy and safety of intravenous fosfomycin for the treatment of carbapenem-resistant Klebsiella pneumoniae","volume":"35","author":"Habibi","year":"2023","journal-title":"J. Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.5005\/jp-journals-10071-23958","article-title":"A Real-world Study on Prescription Pattern of Fosfomycin in Critical Care Patients","volume":"25","author":"Zirpe","year":"2021","journal-title":"Indian J. Crit. Care Med."},{"key":"ref_44","first-page":"216","article-title":"Regulation of kidney on potassium balance and its clinical significance","volume":"75","author":"Xie","year":"2023","journal-title":"Sheng Li Xue Bao"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/cc11454","article-title":"Diagnosis, evaluation, and management of acute kidney injury: A KDIGO summary (Part 1)","volume":"17","author":"Kellum","year":"2013","journal-title":"Crit. Care"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e017996","DOI":"10.1136\/bmjopen-2017-017996","article-title":"PIRATE project: Point-of-care, informatics-based randomised controlled trial for decreasing overuse of antibiotic therapy in Gram-negative bacteraemia","volume":"7","author":"Huttner","year":"2017","journal-title":"BMJ Open"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1473-3099(16)00053-0","article-title":"Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: A randomised, controlled, open-label trial","volume":"16","author":"Beishuizen","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jchromb.2015.03.029","article-title":"A validated method for the quantification of fosfomycin in human plasma by liquid chromatography-tandem mass spectrometry","volume":"990","year":"2015","journal-title":"J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/6\/548\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:41:38Z","timestamp":1760031698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/6\/548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["antibiotics14060548"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14060548","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]}}}